Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab versus risedronate in glucocorticoid-treated adults
2010-024393-19Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glucocorticoid-induced osteoporosis (GIOP) comparing Denosumab with Risedronate (2 arms). Primary endpoint: Percent change from baseline in lumbar spine bone mineral density at 12 months. Started Jan 2012; status: completed.
02
Drugs
denosumabrisedronate
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on 2010-024393-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024393-19.